Life Science Nation Newsletter  |  March 31, 2016  |  Issue 156

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Mar. 24 - Mar. 30)
Seeking Therapeutic Opportunities with a China Angle
Invests In B2B Healthcare IT and Approved Medical Devices
Seeks Therapeutics, Medtech and Advanced Life Science Tools Worldwide
Seeks Assets in Oncology, Neurodegenerative Diseases, and Immunology
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI San Francisco 2016 Investors Panel

Video Recap of RESI@TMCx 2015

By Dennis Ford, Founder & CEO, LSN

When LSN founded the Redefining Early Stage Investments (RESI) conference in 2013, it was with the simple hope of creating an event that offered more to early stage life science investors and CEOs than the other partnering events that existed at the time. LSN's business development team had visited partnering events and investor conferences throughout the USA and also internationally, and had met few active early stage investors at these events. As LSN began to cultivate relationships with these firms and discover what kinds of technologies they were seeking to invest in, we saw the opportunity to create an event that would bring these investors together to meet with fundraising CEOs whose technologies matched their investment mandates.

We're now approaching the 8th RESI event, and over the last three years thousands of entrepreneurs and investors have come face to face at RESI to talk about new healthcare technologies...

By Lucy Parkinson, Director of Research, LSN

Family offices often catch the interest of entrepreneurs due to the possibility of committed, long-term capital from investors who look to the long view regarding their investment decisions.  Family offices may also have unique investment motivations that relate to the family's particular expertise and history.  With a reputation for being deep-pocketed and flexible investors, life science CEOs are often interested in meeting with family office investors, and this panel will allow the RESI@TMCx audience to learn directly from family office investment staff about how they invest, what they look for in a life science opportunity, and how to find alignment with their needs.

Moderated by Colin Widen, CEO, Boston Innovation Capital, the panelists are:
  • Julia Belaya, Corporate Partnerships, Plug And Play Ventures
  • Bobby Hatcher, President & CEO, Cockrell Interests
  • Sean Kearney, Managing Director, Three Leaf Ventures
  • Jason Rieger, SVP of Business Development & Portfolio Management, PBM Capital
By Shaoyu Chang, MD, MPH, Senior Research Manager, LSN

The RESI team is pleased to debut a new panel on Healthcare System Partners at RESI@TMCx on April 11. In an article titled "Innovation as Discipline, Not Fad," the New England Journal of Medicine called on healthcare organizations to embrace innovations and serve as the training ground to test their medical benefits, technical feasibility, and business viability. Many healthcare systems are doing just that. This panel will reveal the changing role healthcare organizations are playing in fostering innovation.

Moderated by Rebecca Kaul, Chief Innovation Officer, MD Anderson, this session will feature:
  • Cheng-Kai Kao, Medical Director of Informatics, University of Chicago Medical Center
  • Sharmila Anandasabapathy, Vice President, Global Initiative, Baylor College of Medicine
  • James Hury, Director of Finance, Texas Children's Hospital

Life Science Nation | 9B Hamilton Place | Boston | MA | 02108